bpc-157 clinical trial human 2024 2025 If worked as well as the internet says it does… …we'd probably have high quality trials by now. Instead we have... Lots of rat studies. Lots of podcasts. Lots of Peptides for Recovery: TB500 vs

In animal models, TB-500 increased re-epithelialization rates and accelerated wound closure compared to placebo controls.- Clinical trials with thymosin beta-4 analogues showed improved outcomes in patients with chronic pressure ulcers.- BPC-157 studies demonstrated higher collagen deposition, angiogenesis, and granulation tissue formation in injured tissue models

If weight changes occur, they're more plausibly secondary effectsthrough improved recovery, training consistency, or routine adherencerather than guaranteed fat loss

In this model, tumors develop sequentially in mice carrying the transgene, initiating as non-angiogenic clusters of dysplastic cells, of which a proportion later develop to small angiogenic tumor islets that can progress to large vascularized tumors that metastasize to the lung

[11] [12] The measured endpoint in that combined-genotype work was folate deficiency rather than a B12-specific outcome, so the fair reading is that stacking one-carbon-cycle variants strains the shared methylation machinery, not that it selectively depletes B12